地西他滨治疗骨髓增生异常综合征对JAK2基因表达的影响

Effect of Decitabine on Expression of JAK2 Gene in Treatment of Myelodysplastic Syndrome

目的观察地西他滨治疗骨髓增生异常综合征(MDS)的临床效果及对JAK2基因表达水平的影响。方法选择2011年10月—2014年10月确诊为骨髓增生异常综合征-原始细胞过多性难治性贫血(MDS-RAEB)的患者9例,并选择同期健康体检者21例作为对照组。MDS-RAEB患者给予地西他滨治疗,观察临床效果,检测对照组及MDS-RAEB患者治疗前、治疗2和4个周期后外周血中JAK2-V617F基因的表达水平。结果 MDS-RAEB患者治疗2和4个周期后疾病控制率分别为77.8%和88.9%,总体有效率分别为33.3%和55.6%。MDS-RAEB患者外周血中JAK2-V617F基因表达水平高于对照组,治疗2、4个周期后低于治疗前,且治疗4个周期后低于治疗2个周期(P<0.05)。结论地西他滨治疗MDS-RAEB效果满意,可抑制JAK2-V617F基因的表达。

Objective To observe clinical effectiveness of Decitabine in treatment of myelodysplastic syndrome（ MDS） and effect on expression of JAK2 gene. Methods A total of 9 patients with MDS-refractory anemia with excessive blasts（ MDS-RAEB） during October 2011 and October 2014 were selected as observation group,and 21 healthy controls receiving medical examination at the same time were selected as control group. Patients with MDS-RAEB were treated with Decitabine. Effectiveness was observed,and expressions of JAK2-V617 F gene in peripheral blood were detected before and 2 and 4 weeks after treatment. Results The control rates were 77. 8% and 88. 9% respectively 2 and 4weeks after treatment,and overall effective rates were 33. 3% and 55. 6% respectively in observation and control groups.Expression of JAK2-V617 F gene in peripheral blood of MDS-RAEB patients was significantly increased compared with that in control group,and the expressions 2 and 4 weeks after treatment were significantly decreased than before treatment in MDS-RAEB patients,and the value 4 weeks after treatment was much decreased than that 2 weeks after treatment（ P〈0. 05）. Conclusion Decitabine in treatment of myelodysplastic syndrome can inhibit expression of JAK2 V617 F gene of MDS RAEB patients with satisfactory effect.